Work characterising the neuropathology of patients with psychiatric-onset DLB to determine the potential influence of mixed comorbidities (e.g. synucleinopathy, amyloid, tau) could provide a greater understanding of the underpinning neurobiological processes. This evidence concerns the gene MAPT and synucleinopathy.